This study is a long-term follow-up protocol for patients who participated in study NK-104-3.01EU or study NK-104-3.02EU.

Patients from the NK-104-3.01EU and NK-104-3.02EU studies will continue to receive either pitavastatin or the comparator statin for 1 year.

Inclusion Criteria:

• Patients have completed 12 weeks of treatment in Study NK-104-301 (NCT00249249) or NK-104-302 (NCT00309777)
• Patients who have not developed any treatment emergent and, in the opinion of the investigator, related adverse event (AE) of clinical significance where the investigator is uncomfortable with continuing the patient on therapy with pitavastatin.
• Patients who have been following a fat and cholesterol restrictive diet.

Exclusion Criteria:

• Any conditions which may cause secondary dyslipidemia should be reassessed at the beginning of the follow-up study.
• Uncontrolled diabetes mellitus should be reassessed at the beginning of the follow-up study.
• Abnormal pancreatic, liver, or renal function
• Abnormal serum ALAT/SGPT/ALT, ASAT/SGOT/AST, or creatine kinase (CK) above the pre-specified level
• Significant heart disease